Opinion | Texas Is the Future of America

The idea of the Lone Star State as a herald of the national future is terrifying and not just to liberals. 

Pressure Grows on U.S. Companies to Share Covid Vaccine Technology

Moderna accepted $2.5 billion in taxpayer money to develop its Covid-19 vaccine. But officials in the U.S. and overseas are having trouble persuading the company to license its technology.

Opinion | What if the Coronavirus Crisis Is Just a Trial Run?

The year 2020 gave us a glimpse of something radically new: tensions in politics, finance and geopolitics intersecting with a natural shock on a global scale.

U.S. Officials Press Pfizer for More Evidence of Need for Booster Shot

After meeting with company representatives, officials said the decision would depend partly on data on infections in vaccinated people that cause serious disease or hospitalization.

Novavax Offers U.S. a Fourth Strong Covid-19 Vaccine

The company’s large U.S. trial found an efficacy rate of about 90 percent. But at this point, the nation is awash in other shots.

Brazil’s Bid to Outsource Amazon Conservation Finds Few Takers

Brazil is seeking to share the cost and burden of protecting the rainforest with the private sector. But it has found few firms willing to help.